Vimta Labs growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+18.4%+9.9%−0.7%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+16.0%+45.8%−10.6%
+12.8%+74.6%−21.2%
+15.1%+73.5%−18.0%
−42.5%+72.8%−18.0%
+20.5%+17.8%+9.9%
+20.6%+19.8%+12.7%
+55.5%+60.2%−31.7%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

VIMTALABS₹469.65

Vimta Labs Limited

· Pharma & Health
₹ CrorePeersSUVENTAKEMcap ₹2,098 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—-0.7+9.9+18.4—
EBITDA Growth—-10.6+45.8+16.0—
EBIT Growth—-21.2+74.6+12.8—
Net Income Growth—-18.0+73.5+15.1—
EPS Growth—-18.0+72.8-42.5—
Total Assets Growth—+9.9+17.8+20.5—
Total Equity Growth—+12.7+19.8+20.6—
Cash from Operations Growth—-31.7+60.2+55.5—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.